Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12798874 | 0.89 | TDP1 (0.62) | TSHRTDP1POLBMEN1KMT2A | |
| SCHEMBL4588943 | 0.86 | TDP1 (0.58) | TSHRTDP1POLBMEN1KMT2A | |
| SCHEMBL11295679 | 0.84 | TDP1 (0.56) | TSHRTDP1POLBMEN1KMT2A | |
| SCHEMBL992165 | 0.84 | TDP1 (0.61) | TSHRTDP1POLBMEN1KMT2A | |
| SCHEMBL10608137 | 0.84 | TSHR (0.58) | TSHRPOLBMAPTALDH1A1CYP3A4 | |
| SCHEMBL5952783 | 0.83 | TSHR (0.56) | TSHRTDP1POLBMEN1KMT2A | |
| SCHEMBL27947665 | 0.83 | TDP1 (0.55) | TSHRTDP1POLBMEN1KMT2A | |
| SCHEMBL28618452 | 0.82 | TSHR (0.51) | TSHRTDP1POLBMEN1KMT2A | |
| SCHEMBL8781834 | 0.82 | LMNA (0.55) | TSHRTDP1POLBMEN1KMT2A | |
| SCHEMBL30989211 | 0.82 | TDP1 (0.62) | TSHRTDP1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025016273-A1 | ISOQUINOLINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USES OF ISOQUINOLINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION | 拜西欧斯（北京）生物技术有限公司 | 2025-01-23 | — | — | WO | disclosed |
| CN-110035739-A | Dye composite comprising 12- hydroxy stearic acid, organic amine and dyestuff | 欧莱雅 | 2019-07-19 | — | — | CN | disclosed |
| WO-2017008708-A1 | METHOD FOR PREPARING INDAZOLE COMPOUND AND USE THEREOF | 中国科学院上海药物研究所 | 2017-01-19 | — | — | WO | disclosed |
| WO-2015057963-A1 | FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | disclosed |
| US-20080287430-A1 | Furan Compounds Useful As Ep1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| EP-1874749-A1 | FURAN COMPOUNDS USEFUL AS EPl RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-01-09 | — | — | EP | disclosed |
| EP-1874776-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006114272-A1 | FURAN COMPOUNDS USEFUL AS EPl RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006114274-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
| EP-1212096-A2 | DRUG CONJUGATES AND METHODS OF DESIGNING THE SAME | Brenner, Sydney (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001013958-A2 | DRUG CONJUGATES AND METHODS OF DESIGNING THE SAME | BRENNER SYDNEY (US) | 2001-03-01 | — | — | WO | disclosed |
| EP-0035671-A1 | Water-insoluble azo dyestuffs, methods for their preparation and their use in dyeing and printing synthetic hydrophobic fibre materials | CASSELLA Aktiengesellschaft (DE) | 1981-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | PTGER1, PTGER2, PTGER4 | TSHR 322/4885TDP1 4108/4885POLB 2637/4885 |
| US-20080287430-A1 | Furan Compounds Useful As Ep1 Receptor Antagonists | PTGER1, PTGER2, PTGER3 | TSHR 277/4885TDP1 3873/4885POLB 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.